My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

4.940 -0.110 (-2.18%)
Streaming Delayed Price Updated: 11:44 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Changes to the Executive Leadership Team
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
From Ardelyx, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
From Ardelyx, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Award established to recognize leaders in the field of chronic kidney disease advocacy 
From Ardelyx, Inc.
Via GlobeNewswire
Tenapanor Approved in China for Hyperphosphatemia
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.